Another phase II study investigated the effects of erlotinib in 64 MM patients and examined these effects with respect to the expression of EGFR, phospho-EGFR, HER2, phospho-ERK, phospho-AKT and PTEN [125]. The gene discussed is EGFR; the disease is Miyoshi myopathy.